Overview
Status
Active
Registry date
2011-09-09
Share capital
10 050,00 PLN
Registered address
ul. Józefa Piusa Dziekońskiego 3, 00-728 Warszawa, Poland
Website
synektik.com.plWebsite active
Electronic delivery address
AE:PL-61568-32596-VUFGS-34
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 13.22mMedianUSD 816.16kAverageUSD 29.28m
Net profit
This companyUSD 2.01mMedianUSD 8.96kAverageUSD 2.64m
Operating costs
This companyUSD 10.17mMedianUSD 701.47kAverageUSD 19.26m
Assets
This companyUSD 12.07mMedianUSD 800.13kAverageUSD 29.34m
Industry
Bank accounts
Registered as a VAT taxpayer on 2011-09-14. Active
11 1030 1508 0000 0008 2263 0002
16 1090 1056 0000 0001 4265 4650- 24 1090 1056 0000 0001 4265 4700
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
7 public aid cases recorded, with a total value of $870,982.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $11,158$11,158 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $11,568$11,568 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $11,060$11,060 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2018-10-01 | Rozwój zaplecza badawczo-rozwojowego Synektik Pharma w celu opracowania nowych radiofarmaceutyków specjalnych do celowanej diagnostyki onkologicznej i neurologicznej metodą Pozytonowej Tomografii Emisyjnej (PET) | $428.7K$428,663 | Program Operacyjny Inteligentny Rozwój | |
| 2018-06-01 | Wprowadzenie na rynek nowego radiofarmaceutyku 18F-fluorotymidyny (FLT) do celowanej diagnostyki onkologicznej i oceny postepów terapii. | $227.6K$227,581 | Program Operacyjny Inteligentny Rozwój |
Tenders
70 tenders recorded as contractor: 31 national ($4,169,254) and 39 EU ($40,406,151).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Sep 29, 2026 | Dostawa materiałów radioizotopowych | —— | Mazowiecki Szpital Wojewódzki Im. Św. Jana Pawła II w Siedlcach sp. z o.o. | |
| Aug 17, 2026 | Zakup i dostawa radiofarmaceutycznych produktów leczniczych stosowanych w ramach programu lekowego i poza programem oraz wyrobów medycznych | $1.4M$1,402,432 | Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego | |
| Jul 2, 2026 | EZ.271.228.2025 Postępowanie o udzielenie zamówienia publicznego na dostawę wyrobów medycznych dla Wojewódzkiego Wielospecjalistycznego Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi prowadzonego w trybie przetargu nieograniczonego o wartości powyżej 10 000 000 Euro. | $2.4M$2,405,239 | Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii Im.M.Kopernika w Łodzi |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Przemysław Bolesław Kozanecki — President of the Management Board
Manner of representation
In the case of a one-person management board, each member of the management board acting independently. In the case of a multi-member management board, the President of the Management Board independently, or two members of the management board acting jointly, or one member of the management board acting jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 201 | $2,714.75 | 100% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Przemysław Bolesław Kozanecki (57)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | — | glagolica.eu |
Change history
| Date | Event | |
|---|---|---|
| 2021-08-12 | Address change (Aleja Wincentego Witosa 31, 00-710, Warszawa → Ul. Józefa Piusa Dziekońskiego 3, 00-728, Warszawa) | |
| 2018-08-24 | Share capital change (10,500.00 PLN → 10,050.00 PLN) | |
| 2018-07-04 | Share capital change (5,050.00 PLN → 10,500.00 PLN) | |
| 2018-05-10 | Address change (Piękna 15/12, 00-549, Warszawa → Aleja Wincentego Witosa 31, 00-710, Warszawa) | |
| 2018-05-10 | Name change (Monrol Poland Ltd → Synektik Pharma) |
FAQ
Last updated: 2026-03-31